Download PDF
Int J Angiol
DOI: 10.1055/s-0044-1788893
Review Article

The Year in Cardiology—Practice Changing Trials from European Society of Cardiology Congress 2023

Akshyaya Pradhan 
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Umesh Tripathi
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Abhishek Singh
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The European Society of Cardiology annual congress is the premier global platform for dissemination and unraveling major scientific advances in the field of cardiology. Each year a myriad number of scientific ideas are exchanged at this meeting and many major path-breaking clinical trials are presented that have the potential to alter our practice. Last year was not different and more than 30 clinical trials spanning various facets of cardiology were unveiled and discussed—heart failure, lipid lowering, coronary intervention, intracoronary imaging, cardiomyopathies, anticoagulation, atrial fibrillation, antiplatelet therapy, etc. We present a brief summary of 10 major trials which in the view of authors have the potential for impacting daily cardiology practice. In each study, we also attempt to provide a contemporary perspective and the way forward. We aim to provide a glimpse on the major advances in the field of cardiology in the past year.

Keywords

semaglutide - stent thrombosis - acute heart failure - frailty - complete revascularization - subclinical AF - bifurcation lesion - postprocedural anticoagulation - cardiac myosin inhibitors - statins

Authors' Contributions

A.P., U.T., and A.S. conceptualized the study and prepared the manuscript. A.P. and U.T. designed the study, and contributed to literature search and manuscript editing. A.P. and A.S. contributed to definition of intellectual content and manuscript review. A.P. is the guarantor.




Publication History

Article published online:
13 August 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Wilding JPH, Batterham RL, Calanna S. et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384 (11) 989-1002
    CrossrefPubMedGoogle Scholar
  • 2 Kosiborod MN, Abildstrøm SZ, Borlaug BA. et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with Heart Failure with Preserved Ejection Fraction and obesity. N Engl J Med 2023; 389 (12) 1069-1084
    CrossrefPubMedGoogle Scholar
  • 3 Natsuaki M, Morimoto T, Yamamoto E. et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016; 31 (03) 196-209
    CrossrefPubMedGoogle Scholar
  • 4 Watanabe H, Domei T, Morimoto T. et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321 (24) 2414-2427
    CrossrefPubMedGoogle Scholar
  • 5 Natsuaki M, Watanabe H, Morimoto T. et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation 2024; 149 (08) 585-600
    CrossrefPubMedGoogle Scholar
  • 6 Mehta SR, Wood DA, Storey RF. et al; COMPLETE Trial Steering Committee and Investigators. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 381 (15) 1411-1421
    CrossrefPubMedGoogle Scholar
  • 7 Stähli BE, Varbella F, Linke A. et al; MULTISTARS AMI Investigators. Timing of complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2023; 389 (15) 1368-1379
    CrossrefPubMedGoogle Scholar
  • 8 Yan Y, Wang X, Guo J. et al. Rationale and design of the RIGHT trial: a multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am Heart J 2020; 227: 19-30
    CrossrefPubMedGoogle Scholar
  • 9 Choi JH, Seo JM, Lee DH, Park K, Kim YD. Clinical utility of new bleeding criteria: a prospective study of evaluation for the Bleeding Academic Research Consortium definition of bleeding in patients undergoing percutaneous coronary intervention. J Cardiol 2015; 65 (04) 324-329
    CrossrefPubMedGoogle Scholar
  • 10 Cox ZL, Collins SP, Hernandez GA. et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 2024; 83 (14) 1295-1306
    CrossrefPubMedGoogle Scholar
  • 11 Kosiborod MN, Angermann CE, Collins SP. et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 2022; 146 (04) 279-288
    CrossrefPubMedGoogle Scholar
  • 12 Olivotto I, Oreziak A, Barriales-Villa R. et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396 (10253): 759-769
    CrossrefPubMedGoogle Scholar
  • 13 Desai MY, Owens A, Geske JB. et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022; 80 (02) 95-108
    CrossrefPubMedGoogle Scholar
  • 14 Desai MY, Owens A, Wolski K. et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol 2023; 8 (10) 968-977
    CrossrefPubMedGoogle Scholar
  • 15 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    CrossrefPubMedGoogle Scholar
  • 16 Joosten LPT, van Doorn S, van de Ven PM. et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 2024; 149 (04) 279-289
    CrossrefPubMedGoogle Scholar
  • 17 Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc 2017; 6 (07) e005835
    CrossrefPubMedGoogle Scholar
  • 18 Nissen SE, Tuzcu EM, Schoenhagen P. et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (01) 29-38
    CrossrefPubMedGoogle Scholar
  • 19 Lee YJ, Hong SJ, Kang WC. et al; LODESTAR investigators. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ 2023; 383: e075837
    CrossrefPubMedGoogle Scholar
  • 20 Healey JS, Connolly SJ, Gold MR. et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366 (02) 120-129
    CrossrefPubMedGoogle Scholar
  • 21 Kirchhof P, Blank BF, Calvert M. et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH-AFNET 6) trial. Am Heart J 2017; 190: 12-18
    CrossrefPubMedGoogle Scholar
  • 22 Camm AJ, Simantirakis E, Goette A. et al. Atrial high-rate episodes and stroke prevention. Europace 2017; 19 (02) 169-179
    CrossrefPubMedGoogle Scholar
  • 23 Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, Osborn EA. Intravascular ultrasound imaging–guided versus coronary angiography–guided percutaneous coronary intervention: a systematic review and meta-analysis. J Am Heart Assoc 2020; 9 (05) e013678
    CrossrefPubMedGoogle Scholar
  • 24 Holm NR, Andreasen LN, Walsh S. et al. Rational and design of the European randomized optical coherence tomography optimized bifurcation event reduction trial (OCTOBER). Am Heart J 2018; 205: 97-109
    CrossrefPubMedGoogle Scholar